This segment focuses on the research, development, and clinical evaluation of precision oncology medicines. Acrivon utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to identify patients most likely to benefit from its drug candidates. R&D activities include target identification, drug discovery, preclinical studies, and clinical trials. The primary technology is the AP3 platform, which enables the creation of OncoSignature companion diagnostics. The therapeutic areas include platinum-resistant ovarian, endometrial, and bladder cancer, with the lead candidate ACR-368, a CHK1/CHK2 inhibitor, in Phase II trials. Patient impact is addressed by providing targeted therapies to patients with high unmet medical needs. Market positioning is based on the ability to match the right drug to the right patient, potentially improving efficacy and reducing side effects. Future opportunities include expanding the pipeline and developing companion diagnostics. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. Partnerships include collaborations with Akoya Biosciences for companion diagnostic development.